Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan(University of Minnesota), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Université de Lille), Paul de Souza(St. George Hospital), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Josep M. Piulats(Institut Català d'Ornitologia), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Eric Winquist(Western University), Daniel J. George(Duke University), Fred Saad(Centre Hospitalier de l’Université de Montréal), Thian Kheoh(Janssen (United States)), Hendrik Van Poppel(Universitair Ziekenhuis Leuven), Peter F.A. Mulders(Radboud University Nijmegen), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Youn Park(Janssen (Belgium)), Evan Y. Yu(University of Washington), Thomas W. Flaig(University of Colorado Denver), Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Matthew R. Smith(Massachusetts General Hospital), Arturo Molina(Janssen (United States)), Dirk Schrijvers(ZNA Middelheim Hospital), Som D. Mukherjee(Juravinski Cancer Centre), H. Suttmann, Allan J. Pantuck(University of California System), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Siobhan Ng(St John of God Subiaco Hospital), Winald R. Gerritsen(Radboud University Nijmegen), Celestia S. Higano(University of British Columbia), Thomas W. Griffin(Janssen (Belgium)), Joan Carles(Vall d'Hebron Hospital Universitari)
New England Journal of Medicine
December 10, 2012
Cited by 2,789


Related Papers